MRKMerck Sharp & Dohme LLCRunning, no new patients
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Head and Neck Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 714 (final count)
- Started
- Dec 17, 2018
- Main results expected
- Jul 25, 2024
- Fully finished
- Nov 17, 2026
- Results posted
- Aug 20, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-free Survival (EFS)
Measured over: Up to ~66 months
EFS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
Measured over: Up to ~66 months
EFS in Participants With PD-L1 CPS ≥1
Measured over: Up to ~66 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03765918 · record last updated 2026-07-31 · checked 2026-11-09 15:47 UTC